Project Grant R21MH143162
- The National Institute of Mental Health awarded The Leland Stanford Junior University $739,125 for a project grant to decipher the molecular function of fragile X messenger ribonucleoprotein (FMRP) in fragile X syndrome, awarded on August 1, 2026, under the Mental Health Research Grants program (CFDA 93.242). The project investigates FMRP's role in translational regulation and its relationship to fragile X syndrome pathogenesis. Fragile X syndrome, the most prevalent form of inherited...
- The National Institute of Mental Health awarded Cincinnati Children's Hospital Medical Center $723,817 on August 24, 2026, under the Mental Health Research Grants program (CFDA 93.242) to study fragile X syndrome–associated blood-brain barrier defects and hypervascularization using blood-brain barrier assembloid models derived from patient-induced pluripotent stem cells. The research develops and validates BBB assembloid models combining neural and vascular components from fragile X syndrome and...
- The National Institute of Neurological Disorders and Stroke awarded Emory University $234,750 on May 11, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to investigate NMDA receptor regulation of rapid synaptic scaling and spinal excitability in fragile X syndrome. The research will identify mechanisms controlling maturation of network excitability during neonatal development, with focus on how NMDA receptor blockade triggers...
- The National Institute of Mental Health awarded Michigan State University $416,859 on March 3, 2026, under the Mental Health Research Grants program (CFDA 93.242) to probe nucleolus function in a mouse model of Fragile X Syndrome. The research aims to explore nucleolar hyper-function as a novel aspect of FXS pathology. The investigator proposes that this hyper-function drives aberrant ribosome biogenesis, thereby increasing cellular translation capacity and explaining the elevated global protein...
- Federal Project Grant Award Summary Emory University received a $430,375 Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), awarded July 1, 2025, with completion expected June 30, 2027. This award funds research investigating membrane trafficking impairments in Fragile X Syndrome (FXS), the most common form of inherited intellectual disability and...
- The National Institute of Mental Health awarded The Children's Hospital Corporation (Boston Children's Hospital) $497,364 on August 1, 2026, under the Mental Health Research Grants program (CFDA 93.242) to support research on therapeutic targeting of proteostasis in Fragile X Syndrome. The work investigates protein degradation mechanisms in Fragile X Syndrome and tests proteasome inhibition as a novel therapeutic strategy. The research interrogates whether increased ubiquitin proteasome system...
- The National Institute on Aging awarded Emory University $430,375 on May 15, 2026, under the Aging Research program (CFDA 93.866) to investigate the role of N6-methyladenosine (m6a) RNA modification in Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS) pathogenesis. FXTAS is a progressive, late-onset neurodegenerative disorder affecting carriers of CGG premutation expansions in the FMR1 gene, characterized by tremor, gait ataxia, parkinsonism, cognitive decline, and neuropathological features...
- The National Institute of Mental Health awarded The General Hospital Corporation (Massachusetts General Hospital) $824,998 under Project Grant R01MH137056 on June 1, 2026, to investigate r-loop-induced CGG contraction as a therapeutic approach for Fragile X Syndrome. The funded research examines how two compounds—a MEK inhibitor and a BRAF inhibitor—reactivate the silenced FMR1 gene by promoting DNA demethylation and forming site-specific r-loops that recruit endogenous DNA repair mechanisms...
- The National Institute of Child Health and Human Development awarded $429,000 to The Regents Of The University Of Colorado (University of Colorado-Denver) on August 14, 2026, under the Child Health and Human Development Extramural Research program (CFDA 93.865) to characterize Fragile X Syndrome in the human brain using post-mortem human tissue. The research team will study cell-type-specific gene expression in Fragile X Syndrome human brain tissue and investigate length and methylation...
- The National Institute of Mental Health awarded Emory University $100,228 on December 30, 2026, under the Mental Health Research Grants program (CFDA 93.242) to support research on integrated mechanisms for corticostriatal control of action. The award funds investigation of how the orbitofrontal cortex, premotor cortex, and dorsomedial striatum interact to coordinate exploration-exploitation decision-making—the balance between trying new strategies and leveraging proven approaches. The...
The National Institute of Mental Health awarded Emory University $430,375 on August 1, 2026, under the Mental Health Research Grants program (CFDA 93.242) to conduct spatial translational dysregulation research in Fragile X Syndrome. The award funds construction of high-resolution, single-cell maps of translational regulation in Fragile X Syndrome mouse brains using advanced spatial genomics technologies including STARMAP-PLUS and RIBOMAP. Research aims include generating spatial transcriptomics and translatomics maps to quantify the abundance and translation of FMRP-target mRNAs across brain regions and cell types, revealing how loss of FMRP alters mRNA localization and translation. A second aim investigates how synaptic activity modulates spatial mRNA translation by inducing activity-dependent long-term depression in brain slices, establishing the first direct link between synaptic stimulation and localized mRNA translation dynamics in Fragile X Syndrome. Performance occurs in Atlanta, Georgia, with a period running through July 31, 2028. The research addresses translational dysregulation in the most common inherited intellectual disability and a leading monogenic cause of autism spectrum disorder, employing spatial genomics to overcome limitations of bulk transcriptomic methods in understanding FMRP's spatial and activity-dependent regulation in the brain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $430.4k | 7/29/26 |